Literature DB >> 2226572

Fluctuation in the concentrations of vanillylmandelic acid and homovanillic acid in mass screening for neuroblastoma.

M Nishi1, H Miyake, T Takeda, K Yamashiro, N Takasugi, J Hanai, T Kawai.   

Abstract

Fluctuations in the amount of vanillylmandelic acid (VMA) and homovanillic acid (HVA) were studied in random urine samples from 13 infants with neuroblastoma. In patients with a small tumour, many samples contained amounts below the cut off values, suggesting that detection of a patient with neuroblastoma depended on mathematical probability. Using high performance liquid chromatography a patient with a tumour of about 10 g may well be overlooked, whereas a patient whose tumour weighs over 30 g would probably be detected. With qualitative screening, although more likely to miss a patient with low VMA excretion, a patient with a tumour weighing over 50 g would be detected. In a thorough hospital examination care should be exercised in interpreting borderline values of VMA and HVA; excretion information suggesting the existence of a tumour may aid localization by radiological imaging procedures.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2226572     DOI: 10.1007/bf02072074

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Homovanillic acid and vanilmandelic acid in diagnosis of neuroblastoma.

Authors:  C M WILLIAMS; M GREER
Journal:  JAMA       Date:  1963-03-09       Impact factor: 56.272

2.  Effects of the mass screening of neuroblastoma in Sapporo City.

Authors:  M Nishi; H Miyake; T Takeda; M Shimada; N Takasugi; Y Sato; J Hanai
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

3.  Laboratory techniques and neuroblastoma screening.

Authors:  T Sawada
Journal:  Lancet       Date:  1988-11-12       Impact factor: 79.321

4.  Cases of neuroblastoma missed by the mass screening programs.

Authors:  M Nishi; H Miyake; T Takeda; N Takasugi; Y Sato; J Hanai; T Kawai
Journal:  Pediatr Res       Date:  1989-12       Impact factor: 3.756

5.  Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group.

Authors:  T Sawada; M Hirayama; T Nakata; T Takeda; N Takasugi; T Mori; K Maeda; R Koide; Y Hanawa; A Tsunoda
Journal:  Lancet       Date:  1984-08-04       Impact factor: 79.321

6.  Simple liquid-chromatographic measurement of vanillylmandelic acid and homovanillic acid in urine on filter paper for mass screening of neuroblastoma in infants.

Authors:  J Hanai; T Kawai; Y Sato; N Takasugi; M Nishi; T Takeda
Journal:  Clin Chem       Date:  1987-11       Impact factor: 8.327

7.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.

Authors:  H Shimada; J Chatten; W A Newton; N Sachs; A B Hamoudi; T Chiba; H B Marsden; K Misugi
Journal:  J Natl Cancer Inst       Date:  1984-08       Impact factor: 13.506

8.  Determination of urinary vanillylmandelic acid and homovanillic acid by high performance liquid chromatography for mass screening of neuroblastoma.

Authors:  Y Sato; J Hanai; N Takasugi; T Takeda
Journal:  Tohoku J Exp Med       Date:  1986-10       Impact factor: 1.848

9.  Establishment of cut off values for vanillylmandelic acid and homovanillic acid in 24-hr urine accumulation during mass screening for neuroblastoma.

Authors:  M Nishi; H Miyake; T Takeda; N Takasugi; Y Sato; J Hanai
Journal:  Jpn J Clin Oncol       Date:  1987-09       Impact factor: 3.019

10.  Effects of the mass screenings for neuroblastoma in Japan. A study of 68 cases.

Authors:  M Nishi; H Miyake; T Takeda; N Takasugi; Y Sato; J Hanai
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.